Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission

Leukemia

Volumn 23, Issue 4, 2009, Pages 635-640

  Basara, N ^a   Schulze, A ^b   Wedding, U ^c   Mohren, M ^d   Gerhardt, A ^e   Junghanss, C ^f   Peter, N ^g   Dolken G ^h   Becker, C ^a   Heyn, S ^a   Kliem, C ^a   Lange, T ^a   Krahl, R ^a   Ponisch W ^a   Fricke, H J ^c   Sayer, H G ^c   Al Ali, H ^a   Kamprad, F ^a   Niederwieser, D ^a  

^a University Medical Centre   (Germany)

^b HELIOS KLINIKUM ERFURT   (Germany)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^d OTTO VON GUERICKE UNIVERSITY   (Germany)

^e Ernst von Bergmann Clinic   (Germany)

^f UNIVERSITY OF ROSTOCK   (Germany)

^g Carl Thiem Hospital   (Germany)

^h UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTIINFECTIVE AGENT; ATG S; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; FLUDARABINE; FOLINIC ACID; HLA A ANTIGEN; HLA B ANTIGEN; HLA DR ANTIGEN; IDARUBICIN; LEUKOCYTE ANTIGEN; METHOTREXATE; MITOXANTRONE; PREDNISONE; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; CYTOGENETICS; DISEASE FREE SURVIVAL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENGRAFTMENT SYNDROME; GENE DELETION; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HLA MATCHING; HLA TYPING; HUMAN; HUMAN CELL; INCIDENCE; KARYOTYPE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIVING DONOR; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; STEM CELL MOBILIZATION; WHOLE BODY RADIATION;

EID: 64849088683     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.352     Document Type: Article

References (25)

1. Löwenberg B. Post-remission treatment of acute myelogenous leukemia. New Engl J Med 1995; 332: 260-262.
2. Stockerl-Goldstein KE, Blume KG. Allogeneic hematopoietic cell transplantation for adult patients with acute myeloid leukemia. In: Blume KG, Forman SJ, Appelbaum FR (eds). Thomas Hematopoietic Cell Transplantation, 3rd edn. Blackwell Publishing, Carlton, Victoria, Australia, 2004, pp 1025-1039.
3. Mrozek K, Heinonen K, De La Chapelle A, Bloomfield CD. Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol 1997; 24: 17-31.
4. Jourdan E, Maraninchi D, Reiffers D, Gluckman E, Rio B, Jouet JP et al. Early allogeneic transplantation favorably influences the outcome of adult patients suffering from acute myeloid leukemia. Bone Marrow Transplant 1997; 19: 875-881.
5. Burnett AK, Wheatley K, Goldstone AH, Stevens R, Hann I, Hills RK. Long-term results of the MRC AML10 trial. Clin Adv Hematol Oncol 2006; 4: 445-451.
6. Suciu S, Mandelli F, De Witte T, Zittoun R, Gallo E, Labar B et al Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): An intention-totreat analysis of the EORTC/GIMEMAAML-10 trial. Blood 2003; 102: 1232-1240.
7. Frassoni F. Randomised studies in acute myeloid leukaemia: The double truth. Bone Marrow Transplant 2000; 25: 471-473.
8. Burnett AK. Current controversies: Which patients with acute myeloid leukaemia should receive a bone marrow transplantation?-an adult treater's view. Br J Harmatol 2002; 118: 357-364.
9. Wheatley K, Gray R. Commentary: Mendelian randomization - an update on its use to evaluate allogeneic stem cell transplantation in leukaemia. Int J Epidemiol 2004; 33: 15-17.
10. Cornelissen JJ, van Putten WLJ, Verdonck LF, Theobald M, Jacky E, Daenen SMG et al. Results of a HOVON/SAKK donor versus nodonor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 2007; 109: 3658-3666.
11. Niederwieser D, Becker C, Krahl R, Al-Ali HK, Heyn S, Cross M et al Increased leukaemia free survival (LFS) in patients with cytogenetic high risk AML after related or unrelated hematopoietic cell transplantation (HCT) compared to chemotherapy in the OSHO 96 and 2002 studies. Blood 2006; 108: 82a.
12. Petersdorf EW, Gooley T, Malkki M, Anasetti C, Martin P, Woolfrey A et al. The biological significance of HLA-DP gene variation in haematopoietic cell transplantation. Br J Haematol 2001; 112 1-8.
13. Petersdorf EW, Gooley TA, Anasetti C, Martin PJ, Smith AG, Mickelson EM et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood 1998; 92: 3515-3520.
14. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina A-J, Maloney DG et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing highdose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
15. Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier B et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101: 1620-1629.
16. Hegenbart U, Niederwieser D, Sandmaier BM, Maris MB, Stuart M, Greinix H et al. Treatment for acute myelogenous leukemia by low dose total body irradiation (TBI) based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 2006; 24: 444-453.
17. Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250-259.
18. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
19. Fefer A, Cheever MA, Thomas ED, Appelbaum FR, Buckner CD, Clift RA et al. Bone marrow transplantation for refractory acute leukemia in 34 patients with identical twins. Blood 1981; 57: 421-430.
20. Creutzig U, Reinhardt D. Current controversies: Which patients with acute myeloid leukaemia should receive a bone marrow transplantation? - a European view. Br J Haematol 2002; 118: 365-377.
21. Chen AR, Alonzo TA, Woods WG, Arceci RJ. Current controversies: Which patients with acute myeloid leukaemia should receive a bone marrow transplantation? - an American view. Br J Haematol 2002; 118 378-384.
22. Litzow MR, Pérez WS, Klein JP, Bolwell BJ, Camitta B, Copelan EA et al. Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission. Br J Haematol 2002; 119: 1115-1124.
23. Yakoub-Agha I, Mesnil F, Kuentz M, Boiron JM, Ifrah N, Milpied N et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: A prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol 2006; 24: 5695-5702.
24. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2000; 96: 4075-4083.
25. Burnett AK, Wheatley K, Goldstone AH, Stevens RF, Hann IM, Rees JHK et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: Results of the UK MRC AML 10 trial. Br J Haematol 2002; 118: 385-400.